PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carboplatin
Carcinoma, Non-Small-Cell Lung
Drug Administration Schedule
Female
Glutamates
Guanine
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Paclitaxel
Pemetrexed
Proportional Hazards Models
Time Factors
Treatment Outcome
United States